Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model

  • Ebtehal El-Demerdash
  • Somaia A. Abdel-Sattar
  • Wesam M. El-Bakly
  • Eman A. Mohamed
Original Research Article
First Online:
  • 197 Downloads

Abstract

Background and Objectives

Carvedilol is a drug of choice in treatment of portal hypertension. The present study was designed to elucidate the potential role of antifibrotic effects of carvedilol in improving hepatic efficiency and the carvedilol oral pharmacokinetic changes during induction of liver fibrosis.

Methods

Rats were given CCl4 (1 ml/kg, intraperitoneal) twice weekly for 6 weeks and/or co-treated with carvedilol (10 mg/kg, orally) three times weekly on alternating days. Indocyanine green (ICG) clearance test was used as a modality for the measurement of hepatic blood flow. In addition, assessment of serum albumin as a marker of synthetic capacity and immunohistochemical staining of P-glycoprotein (P-gp) expression as a marker of metabolic capacity were done. Furthermore, hydroxyproline and TGF-β1 were detected as markers of liver fibrosis.

Results

The area under plasma concentration–time curve of a single dose of carvedilol was significantly increased, associated with decreased the clearance in rats intoxicated with CCl4 compared to control group. Carvedilol co-treatment in CCl4-intoxicated rats for 6 weeks significantly counteracted the changes in hepatotoxicity markers and histopathological lesions induced by CCl4. In addition, there were no significant alterations in carvedilol pharmacokinetics between control and CCl4-intoxicated rats. Furthermore, carvedilol treatment restored liver efficiency, including synthetic and metabolic capacity as well as hepatic blood flow.

Conclusion

The present study provides evidence underlying the antifibrotic effects of carvedilol and enhancement of hepatic efficiency. In addition, the pharmacokinetic parameters of a single dose of carvedilol are altered in liver fibrosis, manifested as delayed clearance. This was attributed to the reduction of both hepatic blood flow and CYP2D6 expression in the liver. Carvedilol co-treatment in CCl4-intoxicated rats for 6 weeks recovered its pharmacokinetic profile, which is mainly attributed to the impact of pharmacodynamic antifibrotic effects of carvedilol on its own kinetics.

Keywords

CCl4 Liver Fibrosis Carvedilol Hepatic Blood Flow Dansyl Chloride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

Funding

No funding has been received for the conduct of this study.

Conflict of interest

All authors declare that they have no competing financial or personal interest or any kind of conflict of interest relevant to this study.

Ethical approval

All animal procedures were carried out in strict accordance with the internationally accepted principles for laboratory animal use and care. The study was approved by the Research Ethical Committee of the Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

References

  1. 1.
    Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:281–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Moal F, Veal N, Vuillemin E, Barriere E, Wang J, Fizanne L, et al. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol. 2006;12:6639–45.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000;118:1261–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Laleman W, Nevens F. Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding. Minerva Med. 2006;97:325–45.PubMedGoogle Scholar
  5. 5.
    Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010;22:905–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6(5):e010902.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol. 2012;261:292–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcohol Clin Exp Res. 2012;36:1587–99.CrossRefPubMedGoogle Scholar
  9. 9.
    Araujo Junior RF, Garcia VB, Leitao RF, Brito GA, Miguel Ede C, Guedes PM, Araujo AA. Carvedilol improves inflammatory response, oxidative stress and fibrosis, in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells. PLoS One. 2016;11(2):e0148868.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26:335–46.CrossRefPubMedGoogle Scholar
  11. 11.
    Schaefer WH, Politowski J, Hwang B, Dixon F Jr, Goalwin A, Gutzait L, et al. Metabolism of carvedilol in dogs, rats, and mice. Drug Metab Dispos. 1998;26:958–69.PubMedGoogle Scholar
  12. 12.
    Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53:814–22.PubMedGoogle Scholar
  13. 13.
    Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S142–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46:985–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol. 2011;25:319–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Yaoita H, Sakabe A, Maehara K, Maruyama Y. Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation. 2002;105:975–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28:56–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Bayraktar N, Devay SD, Taslipinar MY, Omeroglu S, Gumuslu S, Kavutcum M, Canbolat O. The effects of stobadine on purine metabolism in rats treated with carbon tetrachloride. Turk J Med Sci. 2012;42:894–900.Google Scholar
  19. 19.
    Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Abdel Fattah LE, Mohamed TA, Taha EA. Spectrofluorimetric determination of carvedilol in dosage form and spiked human plasma through derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride. CI CEQ 2010;16:31–8.Google Scholar
  21. 21.
    Hakucho A, Liu J, Liu X, Fujimiya T. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol Res. 2014;44:560–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Breikaa RM, Algandaby MM, El-Demerdash E, Abdel-Naim AB. Multimechanistic antifibrotic effect of biochanin a in rats: implications of proinflammatory and profibrogenic mediators. PLoS One. 2013;8:e69276.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, et al. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol. 2011;55:612–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Nelson DL, Cox MM. The three-dimensional structure of proteins. In: Lehninger AL, editor. Lehninger: principles of biochemistry. 4th ed. New York: Freeman WH; 2004.Google Scholar
  25. 25.
    Mahmud Z, Bachar S, Qais N. Antioxidant and hepatoprotective activities of ethanolic extracts of leaves of premna esculenta Roxb. against carbon tetrachloride-induced liver damage in rats. J Young Pharm. 2012;4:228–34.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ. Hepatic fibrosis and cytochrome P450: experimental models of fibrosis compared to AHR knockout mice. Hepatol Res. 2000;17:112–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Ibrahim ZS, Ishizuka M, Soliman M, ElBohi K, Sobhy W, Muzandu K, et al. Protection by Nigella sativa against carbon tetrachloride-induced downregulation of hepatic cytochrome P450 isozymes in rats. Jpn J Vet Res. 2008;56:119–28.PubMedGoogle Scholar
  28. 28.
    Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990;1:361–5.PubMedGoogle Scholar
  29. 29.
    Wang P, Chaudry IH. Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Am J Physiol. 1996;270:R927–38.PubMedGoogle Scholar
  30. 30.
    Yang YL, Di L, Duan YY, Liu X, Liu J, Yang RJ, et al. A prospective experimental study of liver fibrosis with ultrasound and its correlation with hepatic reserve function and hemodynamics. BMC Gastroenterol. 2012;12:168.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol. 2004;99:1953–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–61.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Ebtehal El-Demerdash
    • 1
    • 2
  • Somaia A. Abdel-Sattar
    • 3
  • Wesam M. El-Bakly
    • 4
  • Eman A. Mohamed
    • 3
  1. 1.Pharmacology and Toxicology Department, Faculty of PharmacyAin Shams UniversityCairoEgypt
  2. 2.Pharmacology and Toxicology Department, Faculty of PharmacyMisr International UniversityCairoEgypt
  3. 3.Pharmacology and Toxicology Department, Faculty of PharmacyAl-Azhar UniversityCairoEgypt
  4. 4.Pharmacology Department, Faculty of MedicineAin Shams UniversityCairoEgypt

Personalised recommendations